| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 19 | 2024 | 331 | 2.710 |
Why?
|
| Biomarkers, Tumor | 36 | 2024 | 1660 | 2.500 |
Why?
|
| Pleural Neoplasms | 12 | 2021 | 201 | 2.180 |
Why?
|
| Immunohistochemistry | 51 | 2024 | 1799 | 1.620 |
Why?
|
| Ubiquitin Thiolesterase | 11 | 2023 | 66 | 1.420 |
Why?
|
| Melanoma | 13 | 2022 | 495 | 1.360 |
Why?
|
| Lung Neoplasms | 21 | 2023 | 2365 | 1.340 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2022 | 298 | 1.210 |
Why?
|
| In Situ Hybridization, Fluorescence | 13 | 2019 | 361 | 1.090 |
Why?
|
| Skin Neoplasms | 13 | 2022 | 620 | 0.960 |
Why?
|
| Kidney Neoplasms | 10 | 2020 | 546 | 0.770 |
Why?
|
| Peritoneal Neoplasms | 8 | 2023 | 184 | 0.760 |
Why?
|
| Diagnosis, Differential | 25 | 2024 | 1546 | 0.730 |
Why?
|
| Adenocarcinoma | 16 | 2019 | 1173 | 0.670 |
Why?
|
| Blood Platelets | 1 | 2021 | 150 | 0.640 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 110 | 0.630 |
Why?
|
| Soft Tissue Neoplasms | 9 | 2012 | 124 | 0.620 |
Why?
|
| Sarcoma | 9 | 2016 | 222 | 0.610 |
Why?
|
| Humans | 205 | 2024 | 93515 | 0.600 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2018 | 1 | 0.580 |
Why?
|
| Nevus, Pigmented | 3 | 2011 | 58 | 0.570 |
Why?
|
| Mammary Neoplasms, Experimental | 8 | 2015 | 129 | 0.550 |
Why?
|
| Neoplasm Proteins | 4 | 2015 | 537 | 0.550 |
Why?
|
| Female | 134 | 2024 | 48702 | 0.540 |
Why?
|
| Deoxycytidine | 1 | 2018 | 208 | 0.530 |
Why?
|
| Ovarian Neoplasms | 11 | 2021 | 797 | 0.510 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 11 | 0.500 |
Why?
|
| Epithelium | 8 | 2017 | 316 | 0.470 |
Why?
|
| Carcinoma | 10 | 2017 | 439 | 0.470 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 35 | 0.460 |
Why?
|
| Galectin 3 | 1 | 2015 | 20 | 0.460 |
Why?
|
| Uterine Cervical Neoplasms | 9 | 2020 | 318 | 0.440 |
Why?
|
| Thyroid Nodule | 1 | 2015 | 60 | 0.430 |
Why?
|
| Aged | 64 | 2024 | 20434 | 0.420 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2014 | 361 | 0.410 |
Why?
|
| Middle Aged | 77 | 2024 | 27573 | 0.410 |
Why?
|
| Male | 98 | 2024 | 44557 | 0.390 |
Why?
|
| Melanocytes | 3 | 2015 | 60 | 0.390 |
Why?
|
| Adult | 79 | 2024 | 27918 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2013 | 457 | 0.370 |
Why?
|
| Biopsy | 16 | 2024 | 1175 | 0.370 |
Why?
|
| Oncogene Proteins, Fusion | 5 | 2021 | 134 | 0.350 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 7061 | 0.340 |
Why?
|
| Mammary Glands, Animal | 4 | 2012 | 81 | 0.320 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2010 | 9 | 0.310 |
Why?
|
| Predictive Value of Tests | 11 | 2024 | 1713 | 0.310 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2008 | 37 | 0.310 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2006 | 20 | 0.310 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2010 | 81 | 0.290 |
Why?
|
| Myoepithelioma | 2 | 2016 | 10 | 0.290 |
Why?
|
| Lung | 14 | 2021 | 1366 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2012 | 3476 | 0.280 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 2 | 2015 | 7 | 0.270 |
Why?
|
| Coagulation Protein Disorders | 1 | 2007 | 2 | 0.270 |
Why?
|
| Vaginitis | 1 | 2007 | 3 | 0.270 |
Why?
|
| Epithelioid Cells | 3 | 2016 | 13 | 0.270 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 402 | 0.270 |
Why?
|
| Receptors, Complement 3d | 2 | 2006 | 14 | 0.260 |
Why?
|
| Plasminogen | 1 | 2007 | 46 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 106 | 0.260 |
Why?
|
| Gene Fusion | 3 | 2017 | 40 | 0.260 |
Why?
|
| Tissue Array Analysis | 6 | 2016 | 134 | 0.260 |
Why?
|
| Breast Neoplasms | 11 | 2011 | 3110 | 0.260 |
Why?
|
| Uveal Neoplasms | 2 | 2020 | 11 | 0.260 |
Why?
|
| Chromosomal Proteins, Non-Histone | 3 | 2013 | 65 | 0.250 |
Why?
|
| Sensitivity and Specificity | 10 | 2018 | 1922 | 0.250 |
Why?
|
| Rhabdoid Tumor | 4 | 2016 | 21 | 0.250 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2014 | 378 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 1001 | 0.240 |
Why?
|
| Receptors, Calcitriol | 2 | 2006 | 131 | 0.240 |
Why?
|
| Estrogens | 3 | 2020 | 195 | 0.240 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 1061 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 14 | 2019 | 572 | 0.230 |
Why?
|
| RNA, Messenger | 10 | 2015 | 2026 | 0.230 |
Why?
|
| Vaginal Neoplasms | 2 | 2020 | 84 | 0.230 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2017 | 60 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 15 | 2008 | 1395 | 0.220 |
Why?
|
| Transcription Factors | 6 | 2014 | 1691 | 0.220 |
Why?
|
| SMARCB1 Protein | 5 | 2016 | 14 | 0.220 |
Why?
|
| Liposarcoma | 1 | 2005 | 10 | 0.220 |
Why?
|
| Sarcoma, Synovial | 2 | 2016 | 20 | 0.220 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2005 | 20 | 0.220 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2020 | 33 | 0.220 |
Why?
|
| Mice | 34 | 2020 | 12269 | 0.220 |
Why?
|
| Carcinogens | 3 | 2020 | 101 | 0.210 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 2 | 2021 | 19 | 0.210 |
Why?
|
| Kidney | 9 | 2012 | 1111 | 0.210 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2024 | 25 | 0.210 |
Why?
|
| Hemangioendothelioma, Epithelioid | 2 | 2014 | 9 | 0.210 |
Why?
|
| Neoplasms, Experimental | 3 | 2012 | 263 | 0.200 |
Why?
|
| Vascular Neoplasms | 2 | 2014 | 21 | 0.200 |
Why?
|
| Phenotype | 9 | 2019 | 2544 | 0.200 |
Why?
|
| Lymphatic Metastasis | 6 | 2010 | 504 | 0.200 |
Why?
|
| Mutation | 13 | 2021 | 4272 | 0.200 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 1234 | 0.200 |
Why?
|
| Prognosis | 8 | 2021 | 3911 | 0.200 |
Why?
|
| Colonic Neoplasms | 4 | 2019 | 579 | 0.190 |
Why?
|
| Necrosis | 3 | 2021 | 204 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 715 | 0.190 |
Why?
|
| Immunoenzyme Techniques | 11 | 2009 | 293 | 0.190 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 4 | 2012 | 122 | 0.190 |
Why?
|
| Animals | 51 | 2020 | 28155 | 0.190 |
Why?
|
| Antigens, Neoplasm | 5 | 2014 | 355 | 0.190 |
Why?
|
| Disease Models, Animal | 14 | 2011 | 2495 | 0.190 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2020 | 30 | 0.180 |
Why?
|
| RNA-Binding Proteins | 2 | 2017 | 306 | 0.180 |
Why?
|
| Streptococcus pyogenes | 5 | 2001 | 35 | 0.180 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 6 | 0.180 |
Why?
|
| Plague | 2 | 2012 | 27 | 0.180 |
Why?
|
| Biopsy, Needle | 8 | 1995 | 225 | 0.170 |
Why?
|
| Cadherins | 5 | 2002 | 180 | 0.170 |
Why?
|
| Repressor Proteins | 2 | 2020 | 443 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2021 | 63 | 0.170 |
Why?
|
| Integrin beta3 | 1 | 2021 | 31 | 0.170 |
Why?
|
| Adenoma | 4 | 2019 | 258 | 0.170 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2020 | 5 | 0.170 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2005 | 155 | 0.170 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2020 | 16 | 0.170 |
Why?
|
| Bone Neoplasms | 3 | 2010 | 313 | 0.160 |
Why?
|
| Mice, Transgenic | 10 | 2011 | 1587 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2011 | 199 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 2 | 2019 | 112 | 0.160 |
Why?
|
| Graft Rejection | 1 | 2006 | 1120 | 0.160 |
Why?
|
| Neoplasms | 7 | 2020 | 3169 | 0.160 |
Why?
|
| Heart Transplantation | 1 | 2006 | 811 | 0.160 |
Why?
|
| Cell Nucleus | 7 | 2020 | 603 | 0.160 |
Why?
|
| MicroRNAs | 2 | 2016 | 580 | 0.160 |
Why?
|
| Melanins | 2 | 2017 | 22 | 0.160 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 11 | 0.150 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 136 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2015 | 554 | 0.150 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2019 | 20 | 0.150 |
Why?
|
| Adnexal Diseases | 1 | 2019 | 22 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2022 | 2465 | 0.150 |
Why?
|
| Contractile Proteins | 1 | 2019 | 52 | 0.150 |
Why?
|
| Dermatofibrosarcoma | 1 | 2019 | 13 | 0.150 |
Why?
|
| Social Isolation | 2 | 2009 | 71 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 74 | 0.150 |
Why?
|
| Paxillin | 2 | 2010 | 59 | 0.150 |
Why?
|
| Hyperplasia | 3 | 2013 | 147 | 0.150 |
Why?
|
| Vena Cava, Superior | 1 | 2019 | 54 | 0.140 |
Why?
|
| Hemangiosarcoma | 2 | 2014 | 16 | 0.140 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 65 | 0.140 |
Why?
|
| Ovarian Follicle | 4 | 2001 | 66 | 0.140 |
Why?
|
| Neoplasm Staging | 13 | 2014 | 2017 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 192 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2016 | 1338 | 0.140 |
Why?
|
| Histones | 2 | 2012 | 361 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 887 | 0.140 |
Why?
|
| Interleukin-15 | 2 | 2012 | 75 | 0.140 |
Why?
|
| PAX8 Transcription Factor | 1 | 2017 | 24 | 0.140 |
Why?
|
| Hemangioma | 2 | 2015 | 63 | 0.140 |
Why?
|
| Omentum | 2 | 2009 | 68 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 326 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2021 | 347 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 17 | 0.130 |
Why?
|
| Macrophages | 4 | 2015 | 610 | 0.130 |
Why?
|
| Ovary | 5 | 2011 | 254 | 0.130 |
Why?
|
| Chemokines | 2 | 2015 | 76 | 0.130 |
Why?
|
| Indoles | 2 | 2011 | 303 | 0.130 |
Why?
|
| Gene Rearrangement | 2 | 2015 | 168 | 0.130 |
Why?
|
| Octamer Transcription Factors | 1 | 2017 | 5 | 0.130 |
Why?
|
| Ubiquitin | 1 | 2018 | 95 | 0.130 |
Why?
|
| Mesenchymoma | 2 | 1996 | 4 | 0.130 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 57 | 0.130 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2017 | 15 | 0.130 |
Why?
|
| Anal Canal | 2 | 2001 | 92 | 0.130 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2017 | 9 | 0.130 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 36 | 0.130 |
Why?
|
| Mucin-1 | 4 | 2001 | 46 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2020 | 317 | 0.130 |
Why?
|
| Endoscopy | 1 | 2020 | 366 | 0.130 |
Why?
|
| Killer Cells, Natural | 2 | 2012 | 286 | 0.130 |
Why?
|
| Trans-Activators | 4 | 2014 | 439 | 0.130 |
Why?
|
| Adolescent | 15 | 2021 | 9606 | 0.120 |
Why?
|
| Young Adult | 8 | 2024 | 6930 | 0.120 |
Why?
|
| Neurilemmoma | 2 | 2016 | 37 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 305 | 0.120 |
Why?
|
| Fecal Incontinence | 1 | 1996 | 59 | 0.120 |
Why?
|
| Nasal Mucosa | 1 | 2017 | 193 | 0.120 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 277 | 0.120 |
Why?
|
| Mice, Nude | 8 | 2015 | 824 | 0.120 |
Why?
|
| Epithelial Cells | 3 | 2010 | 700 | 0.120 |
Why?
|
| Child | 12 | 2016 | 7355 | 0.120 |
Why?
|
| Pneumonia | 3 | 2011 | 193 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 83 | 0.120 |
Why?
|
| Collagen | 3 | 2003 | 304 | 0.120 |
Why?
|
| Mediastinal Neoplasms | 3 | 1999 | 43 | 0.120 |
Why?
|
| Genes, fos | 1 | 2015 | 24 | 0.120 |
Why?
|
| Galectins | 1 | 2015 | 11 | 0.110 |
Why?
|
| Plague Vaccine | 2 | 2012 | 14 | 0.110 |
Why?
|
| Yersinia pestis | 2 | 2012 | 24 | 0.110 |
Why?
|
| Membrane Proteins | 5 | 2012 | 1264 | 0.110 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2011 | 73 | 0.110 |
Why?
|
| Gallbladder Neoplasms | 1 | 1995 | 23 | 0.110 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 1 | 2015 | 35 | 0.110 |
Why?
|
| Chemotaxis | 1 | 2015 | 74 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 873 | 0.110 |
Why?
|
| Carcinoma, Islet Cell | 1 | 1994 | 3 | 0.110 |
Why?
|
| Adenoma, Islet Cell | 1 | 1994 | 28 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2015 | 145 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2715 | 0.110 |
Why?
|
| Cytodiagnosis | 4 | 2021 | 47 | 0.110 |
Why?
|
| Tristetraprolin | 1 | 2014 | 7 | 0.110 |
Why?
|
| Vaccines, Subunit | 2 | 2012 | 54 | 0.110 |
Why?
|
| Racemases and Epimerases | 2 | 2004 | 4 | 0.110 |
Why?
|
| Carbonic Anhydrases | 1 | 2014 | 15 | 0.110 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2014 | 15 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2014 | 66 | 0.110 |
Why?
|
| Tomography, Emission-Computed | 7 | 1998 | 104 | 0.110 |
Why?
|
| Laser Therapy | 3 | 2000 | 151 | 0.100 |
Why?
|
| Thyroid Neoplasms | 2 | 2018 | 442 | 0.100 |
Why?
|
| Estradiol | 2 | 2011 | 247 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 889 | 0.100 |
Why?
|
| Urothelium | 1 | 2014 | 67 | 0.100 |
Why?
|
| Pleurisy | 1 | 2013 | 4 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 8 | 2009 | 1028 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 985 | 0.100 |
Why?
|
| Connective Tissue Diseases | 2 | 2012 | 75 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2006 | 1448 | 0.100 |
Why?
|
| Pleura | 1 | 2013 | 30 | 0.100 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2013 | 46 | 0.100 |
Why?
|
| Bacterial Proteins | 4 | 2001 | 878 | 0.100 |
Why?
|
| Extracellular Matrix | 3 | 2007 | 256 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 2544 | 0.100 |
Why?
|
| Chondrosarcoma | 2 | 2016 | 54 | 0.100 |
Why?
|
| Microscopy, Electron | 8 | 2003 | 439 | 0.100 |
Why?
|
| Hemochromatosis | 1 | 2012 | 12 | 0.090 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 190 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2009 | 99 | 0.090 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2012 | 29 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2015 | 917 | 0.090 |
Why?
|
| Fibrosis | 1 | 2013 | 230 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 4 | 2002 | 223 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 94 | 0.090 |
Why?
|
| Cell Differentiation | 8 | 2014 | 1621 | 0.090 |
Why?
|
| Contrast Media | 2 | 2009 | 988 | 0.090 |
Why?
|
| Clinical Protocols | 3 | 2010 | 154 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 2 | 1989 | 85 | 0.090 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 137 | 0.090 |
Why?
|
| Neutrophils | 6 | 1999 | 324 | 0.090 |
Why?
|
| Skin Diseases | 2 | 2007 | 174 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2013 | 259 | 0.090 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2011 | 6 | 0.090 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2011 | 21 | 0.090 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.090 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2012 | 58 | 0.090 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 64 | 0.090 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2007 | 24 | 0.090 |
Why?
|
| Mitotic Index | 2 | 2022 | 22 | 0.090 |
Why?
|
| Rectal Neoplasms | 3 | 1989 | 132 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 304 | 0.090 |
Why?
|
| Anoikis | 1 | 2011 | 7 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 40 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2011 | 140 | 0.090 |
Why?
|
| Natural Killer T-Cells | 1 | 2011 | 46 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2020 | 178 | 0.080 |
Why?
|
| Carcinoma, Papillary | 2 | 2004 | 159 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 78 | 0.080 |
Why?
|
| Anilides | 1 | 2011 | 45 | 0.080 |
Why?
|
| Mice, Knockout | 5 | 2020 | 2121 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2012 | 797 | 0.080 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2010 | 18 | 0.080 |
Why?
|
| Quinolines | 1 | 2011 | 85 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2010 | 666 | 0.080 |
Why?
|
| Arginase | 1 | 2010 | 15 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 962 | 0.080 |
Why?
|
| Antigens | 1 | 2011 | 224 | 0.080 |
Why?
|
| ras Proteins | 3 | 2010 | 132 | 0.080 |
Why?
|
| HMGB1 Protein | 1 | 2010 | 18 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2008 | 102 | 0.080 |
Why?
|
| Prostatic Neoplasms | 4 | 2004 | 1775 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 6 | 2020 | 3435 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2007 | 137 | 0.080 |
Why?
|
| Adenomyoepithelioma | 1 | 2010 | 1 | 0.080 |
Why?
|
| Exotoxins | 3 | 2001 | 21 | 0.080 |
Why?
|
| Epidermis | 2 | 2015 | 103 | 0.080 |
Why?
|
| Embryonic and Fetal Development | 1 | 1990 | 68 | 0.080 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2010 | 12 | 0.080 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2010 | 8 | 0.080 |
Why?
|
| World Health Organization | 3 | 2021 | 121 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 23 | 0.080 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 15 | 0.080 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2010 | 15 | 0.080 |
Why?
|
| Schwann Cells | 1 | 2009 | 34 | 0.080 |
Why?
|
| Breast Neoplasms, Male | 1 | 2010 | 31 | 0.080 |
Why?
|
| Lipids | 1 | 2011 | 278 | 0.080 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2009 | 6 | 0.080 |
Why?
|
| Ethinyl Estradiol | 1 | 2009 | 16 | 0.080 |
Why?
|
| Norethindrone | 1 | 2009 | 13 | 0.080 |
Why?
|
| Precancerous Conditions | 3 | 2010 | 205 | 0.080 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2010 | 43 | 0.080 |
Why?
|
| Hepatocytes | 1 | 2010 | 129 | 0.080 |
Why?
|
| Peptide Fragments | 3 | 2007 | 470 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 1073 | 0.080 |
Why?
|
| Consensus | 2 | 2024 | 368 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 4 | 2015 | 1101 | 0.070 |
Why?
|
| Gadolinium | 1 | 2009 | 95 | 0.070 |
Why?
|
| Gene Expression | 3 | 2009 | 1301 | 0.070 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2008 | 10 | 0.070 |
Why?
|
| Abscess | 1 | 2009 | 94 | 0.070 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 196 | 0.070 |
Why?
|
| Receptors, Growth Factor | 1 | 2008 | 52 | 0.070 |
Why?
|
| Streptococcal Infections | 3 | 2000 | 56 | 0.070 |
Why?
|
| Gene Dosage | 3 | 2019 | 211 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2008 | 285 | 0.070 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2007 | 61 | 0.070 |
Why?
|
| Lymphangiogenesis | 1 | 2008 | 41 | 0.070 |
Why?
|
| Granulosa Cell Tumor | 1 | 1988 | 3 | 0.070 |
Why?
|
| Virulence Factors | 1 | 2009 | 113 | 0.070 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 81 | 0.070 |
Why?
|
| Risk Factors | 3 | 2016 | 5899 | 0.070 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 1988 | 4 | 0.070 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1988 | 16 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2002 | 1077 | 0.070 |
Why?
|
| Chorionic Villi | 1 | 1988 | 11 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2011 | 2303 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 3 | 2015 | 255 | 0.070 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 1518 | 0.070 |
Why?
|
| Fibrosarcoma | 1 | 1988 | 89 | 0.070 |
Why?
|
| Theilovirus | 1 | 2008 | 15 | 0.070 |
Why?
|
| Chondroma | 1 | 1988 | 7 | 0.070 |
Why?
|
| Demyelinating Diseases | 1 | 2008 | 48 | 0.070 |
Why?
|
| Apoptosis | 3 | 2009 | 1721 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 413 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2012 | 697 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 280 | 0.070 |
Why?
|
| Translocation, Genetic | 2 | 2013 | 248 | 0.070 |
Why?
|
| Biotin | 1 | 1988 | 44 | 0.070 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 555 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 214 | 0.070 |
Why?
|
| Autoradiography | 6 | 2002 | 53 | 0.070 |
Why?
|
| Caprylates | 1 | 2007 | 10 | 0.070 |
Why?
|
| Cartilage | 1 | 1988 | 115 | 0.070 |
Why?
|
| Oxalates | 2 | 1978 | 49 | 0.070 |
Why?
|
| Glycerol | 2 | 1978 | 34 | 0.070 |
Why?
|
| Mucins | 3 | 2001 | 40 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2016 | 3829 | 0.070 |
Why?
|
| Staining and Labeling | 6 | 2009 | 158 | 0.060 |
Why?
|
| Calcinosis | 1 | 2008 | 222 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 4 | 2016 | 47 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2010 | 688 | 0.060 |
Why?
|
| Eosinophilic Granuloma | 1 | 2007 | 10 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 224 | 0.060 |
Why?
|
| Veronica | 1 | 2007 | 1 | 0.060 |
Why?
|
| Survival Rate | 3 | 2020 | 1948 | 0.060 |
Why?
|
| Triamcinolone | 1 | 2007 | 20 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1988 | 86 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2011 | 603 | 0.060 |
Why?
|
| Plants, Medicinal | 1 | 2007 | 39 | 0.060 |
Why?
|
| Time Factors | 9 | 2014 | 5410 | 0.060 |
Why?
|
| Indoprofen | 1 | 1986 | 1 | 0.060 |
Why?
|
| Amyloid | 1 | 2007 | 104 | 0.060 |
Why?
|
| Phenylpropionates | 1 | 1986 | 7 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 776 | 0.060 |
Why?
|
| Atrial Natriuretic Factor | 3 | 1991 | 38 | 0.060 |
Why?
|
| Pneumonia, Aspiration | 1 | 1986 | 20 | 0.060 |
Why?
|
| Papillomavirus Infections | 2 | 2020 | 300 | 0.060 |
Why?
|
| Cell Proliferation | 5 | 2013 | 1741 | 0.060 |
Why?
|
| In Vitro Techniques | 4 | 2000 | 948 | 0.060 |
Why?
|
| Flavonoids | 1 | 2007 | 85 | 0.060 |
Why?
|
| Infant | 3 | 2016 | 3220 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 286 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 418 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 1986 | 53 | 0.060 |
Why?
|
| Radioimmunotherapy | 2 | 1999 | 29 | 0.060 |
Why?
|
| T-Lymphocytes | 3 | 2001 | 1275 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2019 | 9099 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 284 | 0.060 |
Why?
|
| Receptors, Adrenergic, beta | 2 | 1996 | 68 | 0.060 |
Why?
|
| Deoxyglucose | 4 | 1997 | 39 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2016 | 352 | 0.060 |
Why?
|
| Transplantation, Heterologous | 5 | 2006 | 371 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2007 | 756 | 0.060 |
Why?
|
| Hormones | 1 | 1986 | 136 | 0.060 |
Why?
|
| Pancreas | 2 | 2001 | 258 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 1170 | 0.060 |
Why?
|
| Amyloid beta-Peptides | 1 | 2007 | 245 | 0.060 |
Why?
|
| Virulence | 4 | 2012 | 273 | 0.060 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2005 | 6 | 0.060 |
Why?
|
| Diagnostic Errors | 2 | 2005 | 157 | 0.060 |
Why?
|
| France | 2 | 2019 | 53 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 2755 | 0.060 |
Why?
|
| Inclusion Bodies | 2 | 2018 | 31 | 0.060 |
Why?
|
| Ganglioneuroma | 1 | 2005 | 9 | 0.060 |
Why?
|
| Piperazines | 1 | 2007 | 284 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2020 | 147 | 0.060 |
Why?
|
| Cauda Equina | 1 | 2005 | 13 | 0.060 |
Why?
|
| Sarcoma, Ewing | 1 | 2005 | 42 | 0.060 |
Why?
|
| Paraganglioma | 1 | 2005 | 15 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 381 | 0.060 |
Why?
|
| Urethral Neoplasms | 1 | 2005 | 10 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2015 | 10164 | 0.060 |
Why?
|
| Neoplasm Transplantation | 4 | 1991 | 399 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2007 | 247 | 0.050 |
Why?
|
| RNA Interference | 3 | 2013 | 379 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2007 | 331 | 0.050 |
Why?
|
| Nervous System Neoplasms | 1 | 1984 | 10 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 270 | 0.050 |
Why?
|
| Spinal Diseases | 1 | 2006 | 97 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2006 | 312 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 411 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2005 | 481 | 0.050 |
Why?
|
| Rabbits | 6 | 2002 | 618 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2006 | 479 | 0.050 |
Why?
|
| Carcinoma in Situ | 2 | 2000 | 52 | 0.050 |
Why?
|
| Eosinophilia | 2 | 1995 | 87 | 0.050 |
Why?
|
| Celiac Disease | 2 | 2004 | 219 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 353 | 0.050 |
Why?
|
| Sulfates | 1 | 2004 | 51 | 0.050 |
Why?
|
| Inflammation | 1 | 2010 | 1050 | 0.050 |
Why?
|
| Cystadenoma, Serous | 1 | 2004 | 16 | 0.050 |
Why?
|
| Myxoma | 1 | 2004 | 28 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2006 | 362 | 0.050 |
Why?
|
| Sympathetic Nervous System | 1 | 1984 | 99 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2004 | 50 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2004 | 140 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2004 | 61 | 0.050 |
Why?
|
| Spleen | 3 | 2012 | 374 | 0.050 |
Why?
|
| Heart Neoplasms | 1 | 2004 | 52 | 0.050 |
Why?
|
| Peritoneum | 1 | 2023 | 52 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2004 | 146 | 0.050 |
Why?
|
| Base Sequence | 5 | 2013 | 2220 | 0.050 |
Why?
|
| Symporters | 1 | 2004 | 112 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 3 | 1992 | 281 | 0.050 |
Why?
|
| Lymph Nodes | 5 | 2006 | 548 | 0.050 |
Why?
|
| Calcitriol | 1 | 2004 | 173 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 319 | 0.050 |
Why?
|
| Cryopreservation | 3 | 2001 | 71 | 0.050 |
Why?
|
| Lymphotoxin-alpha | 1 | 2003 | 41 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2002 | 42 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2021 | 309 | 0.050 |
Why?
|
| Indium Radioisotopes | 2 | 1993 | 10 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2002 | 57 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2002 | 57 | 0.050 |
Why?
|
| Silicon Dioxide | 1 | 2002 | 39 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2005 | 375 | 0.050 |
Why?
|
| Sarcoidosis | 1 | 2003 | 92 | 0.050 |
Why?
|
| Paget's Disease, Mammary | 1 | 2001 | 3 | 0.050 |
Why?
|
| Paget Disease, Extramammary | 1 | 2001 | 8 | 0.040 |
Why?
|
| Vitamin D | 1 | 2004 | 272 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2002 | 66 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2009 | 784 | 0.040 |
Why?
|
| Keratoacanthoma | 1 | 2001 | 4 | 0.040 |
Why?
|
| Liver | 4 | 2012 | 1210 | 0.040 |
Why?
|
| Rats | 7 | 2009 | 4072 | 0.040 |
Why?
|
| Homeostasis | 1 | 2004 | 460 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 876 | 0.040 |
Why?
|
| Tissue Distribution | 5 | 2005 | 291 | 0.040 |
Why?
|
| Autopsy | 2 | 2021 | 126 | 0.040 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2021 | 9 | 0.040 |
Why?
|
| Hypoxia | 3 | 1991 | 675 | 0.040 |
Why?
|
| Jaw Neoplasms | 1 | 2001 | 6 | 0.040 |
Why?
|
| Superantigens | 1 | 2001 | 24 | 0.040 |
Why?
|
| Fibroma, Ossifying | 1 | 2001 | 5 | 0.040 |
Why?
|
| Mesocolon | 1 | 2001 | 1 | 0.040 |
Why?
|
| Serous Membrane | 1 | 2021 | 6 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2003 | 124 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 691 | 0.040 |
Why?
|
| Thrombosis | 1 | 2004 | 309 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 2001 | 51 | 0.040 |
Why?
|
| Sex Chromatin | 3 | 1976 | 4 | 0.040 |
Why?
|
| Iodine Radioisotopes | 4 | 1997 | 137 | 0.040 |
Why?
|
| Hyperparathyroidism | 1 | 2001 | 65 | 0.040 |
Why?
|
| Syndrome | 4 | 2013 | 437 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 1998 | 234 | 0.040 |
Why?
|
| beta Catenin | 4 | 2007 | 265 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2012 | 712 | 0.040 |
Why?
|
| False Negative Reactions | 3 | 1998 | 59 | 0.040 |
Why?
|
| Femur | 1 | 2021 | 107 | 0.040 |
Why?
|
| Oncogene Fusion | 1 | 2020 | 10 | 0.040 |
Why?
|
| Choristoma | 1 | 2001 | 59 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 121 | 0.040 |
Why?
|
| Deoxyribonucleases | 1 | 2000 | 27 | 0.040 |
Why?
|
| Mitogens | 1 | 2000 | 59 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 660 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 104 | 0.040 |
Why?
|
| Pathologists | 1 | 2021 | 40 | 0.040 |
Why?
|
| Fasciitis, Necrotizing | 2 | 2000 | 11 | 0.040 |
Why?
|
| Transfection | 2 | 2007 | 880 | 0.040 |
Why?
|
| Interleukin-6 | 3 | 2000 | 276 | 0.040 |
Why?
|
| Pregnancy | 3 | 1996 | 3147 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 45 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 135 | 0.040 |
Why?
|
| Adrenal Gland Diseases | 1 | 2000 | 10 | 0.040 |
Why?
|
| Cushing Syndrome | 1 | 2000 | 25 | 0.040 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2001 | 78 | 0.040 |
Why?
|
| Cervix Uteri | 3 | 2000 | 73 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2000 | 137 | 0.040 |
Why?
|
| Cytogenetic Analysis | 2 | 2010 | 71 | 0.040 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2000 | 3 | 0.040 |
Why?
|
| Histiocytosis | 1 | 1999 | 7 | 0.040 |
Why?
|
| Glucose | 2 | 1997 | 692 | 0.040 |
Why?
|
| Cell Line | 5 | 2008 | 2464 | 0.040 |
Why?
|
| Plasmacytoma | 1 | 1999 | 26 | 0.040 |
Why?
|
| Uric Acid | 1 | 2000 | 137 | 0.040 |
Why?
|
| Crohn Disease | 2 | 2003 | 808 | 0.040 |
Why?
|
| Myositis | 2 | 2000 | 18 | 0.040 |
Why?
|
| Pathology, Clinical | 2 | 2010 | 38 | 0.040 |
Why?
|
| Skin | 4 | 2008 | 578 | 0.040 |
Why?
|
| Propanolamines | 2 | 1996 | 21 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1133 | 0.040 |
Why?
|
| Cell Death | 2 | 2011 | 253 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 240 | 0.040 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1999 | 60 | 0.040 |
Why?
|
| Adenomatous Polyps | 1 | 2019 | 15 | 0.040 |
Why?
|
| Tokyo | 1 | 2019 | 3 | 0.040 |
Why?
|
| Genes, erbB-1 | 2 | 2010 | 15 | 0.040 |
Why?
|
| Colitis, Ulcerative | 2 | 2003 | 800 | 0.040 |
Why?
|
| Complement Activation | 1 | 1999 | 84 | 0.040 |
Why?
|
| Pulmonary Blastoma | 1 | 1999 | 5 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2016 | 295 | 0.040 |
Why?
|
| Keratins | 3 | 2007 | 62 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1999 | 83 | 0.040 |
Why?
|
| Cells, Cultured | 5 | 2007 | 2850 | 0.040 |
Why?
|
| Plasma Cells | 1 | 1999 | 84 | 0.040 |
Why?
|
| Phagocytosis | 2 | 2015 | 111 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1996 | 112 | 0.040 |
Why?
|
| North America | 1 | 2019 | 195 | 0.040 |
Why?
|
| Mesonephroma | 1 | 2018 | 5 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 1999 | 204 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 1998 | 444 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 1998 | 11 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 107 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 2 | 1998 | 152 | 0.040 |
Why?
|
| Pulmonary Artery | 3 | 1991 | 333 | 0.040 |
Why?
|
| Cricetinae | 2 | 2010 | 532 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 235 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 1999 | 179 | 0.040 |
Why?
|
| Brain | 4 | 2008 | 2391 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1998 | 96 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 988 | 0.040 |
Why?
|
| Dextrins | 1 | 1998 | 3 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 526 | 0.030 |
Why?
|
| Collagenases | 2 | 1999 | 42 | 0.030 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 1998 | 8 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2000 | 730 | 0.030 |
Why?
|
| Polychlorinated Biphenyls | 1 | 1998 | 9 | 0.030 |
Why?
|
| Chromosomes | 2 | 1975 | 91 | 0.030 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2018 | 68 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 570 | 0.030 |
Why?
|
| United States | 4 | 2012 | 7622 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 67 | 0.030 |
Why?
|
| Brain Diseases, Metabolic | 1 | 1977 | 8 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 2 | 1991 | 369 | 0.030 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 1997 | 5 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2009 | 197 | 0.030 |
Why?
|
| Bronchiectasis | 1 | 1997 | 14 | 0.030 |
Why?
|
| Spinal Cord | 2 | 2008 | 241 | 0.030 |
Why?
|
| Public Opinion | 1 | 2017 | 50 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 327 | 0.030 |
Why?
|
| Desmoplakins | 3 | 2002 | 7 | 0.030 |
Why?
|
| gamma Catenin | 3 | 2002 | 7 | 0.030 |
Why?
|
| alpha Catenin | 3 | 2002 | 7 | 0.030 |
Why?
|
| Sepsis | 1 | 2001 | 388 | 0.030 |
Why?
|
| HIV-1 | 1 | 1998 | 173 | 0.030 |
Why?
|
| Neural Conduction | 1 | 1996 | 71 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2009 | 144 | 0.030 |
Why?
|
| Indium | 2 | 1986 | 3 | 0.030 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1996 | 11 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 1996 | 33 | 0.030 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2016 | 4 | 0.030 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 304 | 0.030 |
Why?
|
| Parity | 1 | 1996 | 97 | 0.030 |
Why?
|
| Cryoprotective Agents | 1 | 1996 | 9 | 0.030 |
Why?
|
| Radioisotopes | 2 | 1986 | 39 | 0.030 |
Why?
|
| Urinary Bladder | 2 | 2000 | 260 | 0.030 |
Why?
|
| Joint Prosthesis | 2 | 1986 | 26 | 0.030 |
Why?
|
| Decidua | 1 | 1996 | 22 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 702 | 0.030 |
Why?
|
| Infertility, Female | 1 | 1997 | 98 | 0.030 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 1996 | 48 | 0.030 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1996 | 41 | 0.030 |
Why?
|
| Intestinal Mucosa | 3 | 2004 | 824 | 0.030 |
Why?
|
| Propylene Glycols | 1 | 1996 | 31 | 0.030 |
Why?
|
| Endometrium | 1 | 1996 | 51 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 161 | 0.030 |
Why?
|
| Osteomalacia | 1 | 1996 | 13 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 383 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2010 | 621 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 2010 | 502 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 1996 | 60 | 0.030 |
Why?
|
| Breast | 2 | 1990 | 294 | 0.030 |
Why?
|
| Cyclohexanes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 177 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 15 | 0.030 |
Why?
|
| Aspergillus fumigatus | 2 | 1993 | 17 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 2015 | 21 | 0.030 |
Why?
|
| Lamin Type A | 1 | 2015 | 26 | 0.030 |
Why?
|
| HMGA2 Protein | 1 | 2015 | 15 | 0.030 |
Why?
|
| Cough | 1 | 1995 | 56 | 0.030 |
Why?
|
| Polyps | 1 | 1995 | 26 | 0.030 |
Why?
|
| Mice, Inbred Strains | 3 | 2008 | 280 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 86 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 1996 | 69 | 0.030 |
Why?
|
| Serine Endopeptidases | 2 | 1993 | 148 | 0.030 |
Why?
|
| Radiology, Interventional | 1 | 1995 | 62 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 1998 | 195 | 0.030 |
Why?
|
| Bile | 1 | 1995 | 60 | 0.030 |
Why?
|
| Phosphates | 1 | 1996 | 165 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 116 | 0.030 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1995 | 23 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 1995 | 72 | 0.030 |
Why?
|
| Bronchitis | 1 | 1994 | 7 | 0.030 |
Why?
|
| Cornea | 1 | 2015 | 55 | 0.030 |
Why?
|
| Granulocytes | 3 | 1997 | 35 | 0.030 |
Why?
|
| Bronchial Provocation Tests | 1 | 1994 | 24 | 0.030 |
Why?
|
| Triazoles | 1 | 2015 | 110 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2007 | 894 | 0.030 |
Why?
|
| Stromal Cells | 1 | 1995 | 151 | 0.030 |
Why?
|
| Sputum | 1 | 1994 | 36 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 1977 | 315 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 254 | 0.030 |
Why?
|
| Bronchi | 1 | 1995 | 225 | 0.030 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2014 | 11 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 367 | 0.030 |
Why?
|
| Leukocyte Count | 4 | 1999 | 210 | 0.030 |
Why?
|
| Mass Screening | 1 | 1999 | 696 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2014 | 1524 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2014 | 46 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1975 | 279 | 0.030 |
Why?
|
| Lipoma | 1 | 1994 | 25 | 0.030 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1994 | 3 | 0.030 |
Why?
|
| Choriocarcinoma | 1 | 1994 | 7 | 0.030 |
Why?
|
| Cystitis | 2 | 2000 | 12 | 0.030 |
Why?
|
| Cat Diseases | 1 | 1994 | 19 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 119 | 0.030 |
Why?
|
| Pneumococcal Infections | 1 | 1994 | 46 | 0.030 |
Why?
|
| Gelatinases | 1 | 1993 | 10 | 0.030 |
Why?
|
| Disease Progression | 2 | 2008 | 1531 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1998 | 701 | 0.030 |
Why?
|
| Infusions, Parenteral | 3 | 1998 | 46 | 0.030 |
Why?
|
| Cardiomegaly | 2 | 1991 | 111 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2009 | 48 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1993 | 44 | 0.030 |
Why?
|
| Thymus Neoplasms | 1 | 1994 | 46 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 893 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1780 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2006 | 271 | 0.020 |
Why?
|
| Premedication | 1 | 1993 | 57 | 0.020 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 1993 | 7 | 0.020 |
Why?
|
| Histocytochemistry | 3 | 1988 | 125 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 133 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1994 | 100 | 0.020 |
Why?
|
| Barrett Esophagus | 1 | 1994 | 94 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 1975 | 280 | 0.020 |
Why?
|
| NIMA-Related Kinases | 1 | 2013 | 7 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2015 | 4560 | 0.020 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2013 | 13 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2014 | 218 | 0.020 |
Why?
|
| Poland | 1 | 2012 | 18 | 0.020 |
Why?
|
| Penis | 2 | 2005 | 61 | 0.020 |
Why?
|
| Laser Capture Microdissection | 1 | 2012 | 20 | 0.020 |
Why?
|
| Random Allocation | 2 | 1993 | 307 | 0.020 |
Why?
|
| Combined Modality Therapy | 4 | 2005 | 1723 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2802 | 0.020 |
Why?
|
| Lymphangioma | 1 | 2012 | 15 | 0.020 |
Why?
|
| Pancreatic Diseases | 1 | 1993 | 58 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 1992 | 6 | 0.020 |
Why?
|
| Hemangioma, Capillary | 1 | 2012 | 8 | 0.020 |
Why?
|
| Hemochromatosis Protein | 1 | 2012 | 7 | 0.020 |
Why?
|
| Endopeptidases | 1 | 1993 | 116 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2012 | 32 | 0.020 |
Why?
|
| Vimentin | 2 | 2007 | 47 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 1995 | 227 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2012 | 41 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2012 | 52 | 0.020 |
Why?
|
| Microbial Viability | 1 | 2012 | 34 | 0.020 |
Why?
|
| Crystallization | 2 | 2006 | 216 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2009 | 436 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 55 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 56 | 0.020 |
Why?
|
| Graft vs Host Disease | 2 | 1992 | 365 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 192 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 392 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2009 | 1245 | 0.020 |
Why?
|
| Shock, Septic | 1 | 1993 | 124 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 2012 | 49 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2006 | 2585 | 0.020 |
Why?
|
| Cell Division | 3 | 2001 | 693 | 0.020 |
Why?
|
| Neuropeptides | 2 | 1990 | 114 | 0.020 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1991 | 17 | 0.020 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2011 | 8 | 0.020 |
Why?
|
| Adenoma, Bile Duct | 1 | 1991 | 4 | 0.020 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 1991 | 4 | 0.020 |
Why?
|
| Neprilysin | 1 | 1991 | 39 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 2011 | 28 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 47 | 0.020 |
Why?
|
| DNA Primers | 2 | 2004 | 531 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 2910 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 296 | 0.020 |
Why?
|
| Tamoxifen | 1 | 1992 | 170 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2011 | 32 | 0.020 |
Why?
|
| Blood Vessels | 2 | 2008 | 91 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2011 | 102 | 0.020 |
Why?
|
| Organoids | 2 | 1989 | 76 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1139 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1991 | 108 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2011 | 133 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 239 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1994 | 344 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 203 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 524 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 543 | 0.020 |
Why?
|
| Pentetic Acid | 2 | 1991 | 14 | 0.020 |
Why?
|
| Jejunal Neoplasms | 1 | 1991 | 9 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2011 | 163 | 0.020 |
Why?
|
| Ileal Neoplasms | 1 | 1991 | 9 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2011 | 56 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2011 | 145 | 0.020 |
Why?
|
| Models, Biological | 2 | 2008 | 1768 | 0.020 |
Why?
|
| Administration, Intravesical | 3 | 1999 | 34 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 1975 | 578 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 1998 | 149 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2010 | 63 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 1991 | 91 | 0.020 |
Why?
|
| HMGB Proteins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Asbestos | 1 | 2010 | 20 | 0.020 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2010 | 12 | 0.020 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2010 | 7 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2479 | 0.020 |
Why?
|
| Cytokines | 2 | 2010 | 863 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2007 | 308 | 0.020 |
Why?
|
| Mesocricetus | 1 | 2010 | 102 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1994 | 292 | 0.020 |
Why?
|
| Brazil | 1 | 2010 | 81 | 0.020 |
Why?
|
| Heart-Lung Transplantation | 1 | 1990 | 20 | 0.020 |
Why?
|
| Cells | 1 | 2010 | 30 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2012 | 293 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 409 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1992 | 283 | 0.020 |
Why?
|
| Amniotic Fluid | 1 | 1990 | 30 | 0.020 |
Why?
|
| Gynecomastia | 1 | 1990 | 8 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2010 | 56 | 0.020 |
Why?
|
| Endocrine Glands | 1 | 2009 | 13 | 0.020 |
Why?
|
| Immune System | 1 | 2011 | 101 | 0.020 |
Why?
|
| Lipid Peroxides | 2 | 1986 | 11 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 321 | 0.020 |
Why?
|
| Corticosterone | 1 | 2009 | 35 | 0.020 |
Why?
|
| Peptide Biosynthesis | 1 | 1989 | 13 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 307 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 1989 | 69 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 164 | 0.020 |
Why?
|
| Gonadotropins | 1 | 2009 | 33 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 657 | 0.020 |
Why?
|
| Respiratory System | 1 | 1990 | 117 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1992 | 454 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2001 | 135 | 0.020 |
Why?
|
| Integrases | 1 | 2009 | 66 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 515 | 0.020 |
Why?
|
| Stress, Mechanical | 2 | 2000 | 248 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2009 | 125 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 1989 | 18 | 0.020 |
Why?
|
| Histological Techniques | 1 | 1988 | 33 | 0.020 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1988 | 13 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 78 | 0.020 |
Why?
|
| Aspergillosis | 1 | 1989 | 39 | 0.020 |
Why?
|
| Theca Cells | 1 | 1988 | 9 | 0.020 |
Why?
|
| Cell Line, Transformed | 2 | 2000 | 152 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 70 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2009 | 170 | 0.020 |
Why?
|
| Trachea | 1 | 1989 | 245 | 0.020 |
Why?
|
| Social Environment | 1 | 2009 | 194 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 2000 | 436 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 165 | 0.020 |
Why?
|
| Sciatic Nerve | 1 | 2008 | 37 | 0.020 |
Why?
|
| Cattle | 1 | 2009 | 397 | 0.020 |
Why?
|
| Microscopy | 1 | 2008 | 89 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2011 | 914 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1988 | 104 | 0.020 |
Why?
|
| Metaplasia | 1 | 1988 | 39 | 0.020 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 10 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 28 | 0.020 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 21 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 246 | 0.020 |
Why?
|
| Doxorubicin | 2 | 2005 | 284 | 0.020 |
Why?
|
| Cytoplasm | 1 | 1988 | 278 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2008 | 170 | 0.020 |
Why?
|
| Aldehydes | 1 | 2007 | 21 | 0.020 |
Why?
|
| Micelles | 1 | 2007 | 53 | 0.020 |
Why?
|
| Complement C4 | 1 | 1987 | 8 | 0.020 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2007 | 14 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 309 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 151 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2007 | 101 | 0.020 |
Why?
|
| Equipment Design | 2 | 2000 | 416 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2011 | 536 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1987 | 126 | 0.020 |
Why?
|
| Erythema | 1 | 2007 | 31 | 0.020 |
Why?
|
| Polyomavirus | 1 | 1987 | 16 | 0.020 |
Why?
|
| Peroxides | 1 | 1986 | 13 | 0.020 |
Why?
|
| Mitosis | 2 | 1999 | 150 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 398 | 0.020 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1986 | 5 | 0.020 |
Why?
|
| Glucosides | 1 | 2007 | 16 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 155 | 0.020 |
Why?
|
| Technetium | 1 | 1986 | 22 | 0.020 |
Why?
|
| Phenols | 1 | 2007 | 41 | 0.020 |
Why?
|
| Injections | 1 | 2007 | 124 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 86 | 0.020 |
Why?
|
| Receptors, Complement 3b | 1 | 2006 | 39 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2006 | 14 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 353 | 0.020 |
Why?
|
| Chromogranin A | 1 | 1986 | 8 | 0.020 |
Why?
|
| Chromogranins | 1 | 1986 | 11 | 0.020 |
Why?
|
| Acid-Base Equilibrium | 1 | 1986 | 34 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2009 | 342 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 203 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1999 | 125 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2009 | 390 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 25 | 0.020 |
Why?
|
| Epitopes | 1 | 1987 | 254 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 1986 | 92 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2006 | 58 | 0.020 |
Why?
|
| von Willebrand Factor | 2 | 1998 | 40 | 0.020 |
Why?
|
| Asthma | 1 | 1994 | 1039 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 122 | 0.020 |
Why?
|
| Ascites | 1 | 1986 | 54 | 0.020 |
Why?
|
| Pericardial Effusion | 1 | 1986 | 18 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2007 | 416 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 756 | 0.020 |
Why?
|
| Chondrocalcinosis | 1 | 2006 | 7 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1986 | 42 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 87 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 173 | 0.010 |
Why?
|
| Stem Cells | 1 | 2008 | 387 | 0.010 |
Why?
|
| Intestine, Large | 1 | 1986 | 15 | 0.010 |
Why?
|
| Splenic Artery | 1 | 1986 | 10 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 2006 | 31 | 0.010 |
Why?
|
| Diverticulum, Colon | 1 | 1986 | 10 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2008 | 419 | 0.010 |
Why?
|
| Colposcopy | 2 | 1999 | 16 | 0.010 |
Why?
|
| Mesenteric Arteries | 1 | 1986 | 29 | 0.010 |
Why?
|
| Infarction | 1 | 1986 | 25 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1986 | 160 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2006 | 66 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2009 | 477 | 0.010 |
Why?
|
| Myocardium | 1 | 1989 | 570 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 216 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 3054 | 0.010 |
Why?
|
| Vaginal Smears | 2 | 1999 | 71 | 0.010 |
Why?
|
| Age Distribution | 1 | 2006 | 206 | 0.010 |
Why?
|
| Chronic Disease | 3 | 1994 | 960 | 0.010 |
Why?
|
| Acute Disease | 2 | 1999 | 841 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 555 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2006 | 161 | 0.010 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 16 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 1004 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 68 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1986 | 106 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 140 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2006 | 674 | 0.010 |
Why?
|
| Genome | 1 | 2008 | 407 | 0.010 |
Why?
|
| Blood Coagulation Disorders | 1 | 1986 | 66 | 0.010 |
Why?
|
| Vinblastine | 1 | 2005 | 85 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1987 | 184 | 0.010 |
Why?
|
| Behcet Syndrome | 1 | 1985 | 15 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1986 | 179 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1987 | 255 | 0.010 |
Why?
|
| Chromatin | 1 | 2008 | 440 | 0.010 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2004 | 20 | 0.010 |
Why?
|
| Urinary Diversion | 1 | 2005 | 42 | 0.010 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 1996 | 23 | 0.010 |
Why?
|
| False Positive Reactions | 2 | 1998 | 212 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2005 | 172 | 0.010 |
Why?
|
| Disease Susceptibility | 2 | 2001 | 220 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2004 | 35 | 0.010 |
Why?
|
| Aneurysm | 1 | 1985 | 57 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 429 | 0.010 |
Why?
|
| Methotrexate | 1 | 2005 | 225 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 282 | 0.010 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2004 | 7 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2005 | 163 | 0.010 |
Why?
|
| Cystadenoma, Papillary | 1 | 2004 | 9 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 244 | 0.010 |
Why?
|
| Glutathione | 1 | 2004 | 105 | 0.010 |
Why?
|
| Cystectomy | 1 | 2005 | 113 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1989 | 1103 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 122 | 0.010 |
Why?
|
| Lymphography | 1 | 1983 | 25 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 123 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 384 | 0.010 |
Why?
|
| Pain | 1 | 1986 | 414 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2012 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 349 | 0.010 |
Why?
|
| Spinal Nerve Roots | 1 | 1983 | 20 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 1983 | 31 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 233 | 0.010 |
Why?
|
| Biomarkers | 2 | 2001 | 1910 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 512 | 0.010 |
Why?
|
| Lymphotoxin-beta | 1 | 2003 | 5 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 460 | 0.010 |
Why?
|
| Cryptorchidism | 1 | 1983 | 12 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2003 | 77 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 757 | 0.010 |
Why?
|
| Cisplatin | 1 | 2005 | 568 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2004 | 162 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2004 | 273 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 347 | 0.010 |
Why?
|
| Duodenum | 1 | 2003 | 110 | 0.010 |
Why?
|
| Testis | 1 | 1983 | 148 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2441 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 244 | 0.010 |
Why?
|
| Ileum | 1 | 2003 | 167 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 1983 | 88 | 0.010 |
Why?
|
| Radiography | 3 | 1992 | 790 | 0.010 |
Why?
|
| Mucin 5AC | 1 | 2001 | 8 | 0.010 |
Why?
|
| Mucin-2 | 1 | 2001 | 12 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1989 | 3830 | 0.010 |
Why?
|
| Cell Count | 2 | 1996 | 197 | 0.010 |
Why?
|
| Cell Movement | 2 | 1997 | 809 | 0.010 |
Why?
|
| Vulva | 1 | 2001 | 23 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 424 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2002 | 66 | 0.010 |
Why?
|
| Scrotum | 1 | 2001 | 14 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 68 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2003 | 208 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1983 | 172 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 2 | 1986 | 140 | 0.010 |
Why?
|
| Warts | 1 | 2001 | 12 | 0.010 |
Why?
|
| Nipples | 1 | 2001 | 37 | 0.010 |
Why?
|
| Menotropins | 1 | 2001 | 20 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 1 | 2001 | 47 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2005 | 478 | 0.010 |
Why?
|
| Vasculitis | 2 | 1995 | 40 | 0.010 |
Why?
|
| Radionuclide Imaging | 3 | 1986 | 189 | 0.010 |
Why?
|
| Peritoneal Diseases | 1 | 2001 | 15 | 0.010 |
Why?
|
| Proteins | 1 | 1986 | 803 | 0.010 |
Why?
|
| Penetrance | 1 | 2001 | 48 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2001 | 111 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 84 | 0.010 |
Why?
|
| Capillary Resistance | 1 | 2000 | 1 | 0.010 |
Why?
|
| Serotyping | 1 | 2000 | 28 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 2000 | 38 | 0.010 |
Why?
|
| Parathyroid Neoplasms | 1 | 2001 | 60 | 0.010 |
Why?
|
| Arthritis, Gouty | 1 | 2000 | 4 | 0.010 |
Why?
|
| Cell Extracts | 1 | 2000 | 14 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 150 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 457 | 0.010 |
Why?
|
| Factor Xa Inhibitors | 1 | 2000 | 24 | 0.010 |
Why?
|
| Capillaries | 1 | 2000 | 83 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 76 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2000 | 186 | 0.010 |
Why?
|
| Radioimmunoassay | 2 | 1990 | 144 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2000 | 150 | 0.010 |
Why?
|
| Age of Onset | 1 | 2001 | 342 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2000 | 179 | 0.010 |
Why?
|
| Adrenalectomy | 1 | 2000 | 44 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 573 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 273 | 0.010 |
Why?
|
| Granuloma, Plasma Cell | 1 | 1999 | 8 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 2000 | 63 | 0.010 |
Why?
|
| Echocardiography | 1 | 2004 | 745 | 0.010 |
Why?
|
| DNA Probes, HPV | 1 | 1999 | 3 | 0.010 |
Why?
|
| Uterine Cervical Diseases | 1 | 1999 | 7 | 0.010 |
Why?
|
| Paraproteinemias | 1 | 1999 | 19 | 0.010 |
Why?
|
| Proviruses | 1 | 1999 | 15 | 0.010 |
Why?
|
| Transformation, Bacterial | 1 | 1999 | 5 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2001 | 613 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1999 | 121 | 0.010 |
Why?
|
| Pericardiectomy | 1 | 1999 | 9 | 0.010 |
Why?
|
| Colon | 1 | 2003 | 540 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 608 | 0.010 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 1999 | 35 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 224 | 0.010 |
Why?
|
| Mediastinum | 1 | 1999 | 43 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 961 | 0.010 |
Why?
|
| Haplotypes | 1 | 2001 | 647 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1998 | 82 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1999 | 147 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1999 | 234 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1998 | 80 | 0.010 |
Why?
|
| Complement C5a | 1 | 1998 | 24 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1998 | 98 | 0.010 |
Why?
|
| Self Tolerance | 1 | 1998 | 26 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 1998 | 77 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1998 | 10 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 1998 | 13 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 1998 | 10 | 0.010 |
Why?
|
| Macrophages, Peritoneal | 1 | 1998 | 25 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 17 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 1229 | 0.010 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 25 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1999 | 314 | 0.010 |
Why?
|
| Diet, Fat-Restricted | 1 | 1998 | 30 | 0.010 |
Why?
|
| Viremia | 1 | 1998 | 51 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1978 | 120 | 0.010 |
Why?
|
| Follicular Atresia | 1 | 1997 | 1 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 826 | 0.010 |
Why?
|
| Freezing | 1 | 1997 | 31 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1997 | 81 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 315 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1998 | 277 | 0.010 |
Why?
|
| Viral Load | 1 | 1998 | 154 | 0.010 |
Why?
|
| Dogs | 2 | 1989 | 634 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1998 | 203 | 0.010 |
Why?
|
| Laparotomy | 1 | 1997 | 63 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1997 | 91 | 0.010 |
Why?
|
| Autoimmunity | 1 | 1998 | 189 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 1999 | 217 | 0.010 |
Why?
|
| Cytoplasmic Granules | 2 | 1989 | 94 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1996 | 34 | 0.010 |
Why?
|
| Hysterectomy | 1 | 1998 | 167 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1996 | 32 | 0.010 |
Why?
|
| Tritium | 1 | 1996 | 116 | 0.010 |
Why?
|
| Propylene Glycol | 1 | 1996 | 1 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 1996 | 3 | 0.010 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1996 | 13 | 0.010 |
Why?
|
| Sulfatases | 1 | 1996 | 3 | 0.010 |
Why?
|
| Blood Volume | 1 | 1996 | 42 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 829 | 0.010 |
Why?
|
| Prolactin | 1 | 1996 | 89 | 0.010 |
Why?
|
| Organ Size | 2 | 1989 | 362 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1996 | 68 | 0.010 |
Why?
|
| Tissue Embedding | 1 | 1995 | 6 | 0.010 |
Why?
|
| Sucrose | 1 | 1996 | 64 | 0.010 |
Why?
|
| Capsaicin | 1 | 1995 | 43 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1995 | 39 | 0.010 |
Why?
|
| Thiolester Hydrolases | 1 | 1995 | 16 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1995 | 51 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1996 | 103 | 0.010 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1995 | 39 | 0.010 |
Why?
|
| Pulmonary Alveoli | 2 | 1986 | 72 | 0.010 |
Why?
|
| Substance P | 1 | 1995 | 62 | 0.010 |
Why?
|
| Immobilization | 1 | 1995 | 22 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1999 | 338 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1996 | 276 | 0.010 |
Why?
|
| Craniotomy | 1 | 1996 | 91 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 1996 | 115 | 0.010 |
Why?
|
| Radiotherapy Dosage | 2 | 1986 | 472 | 0.010 |
Why?
|
| Quinacrine | 1 | 1975 | 10 | 0.010 |
Why?
|
| Wolffian Ducts | 1 | 1995 | 8 | 0.010 |
Why?
|
| Karyotyping | 1 | 1975 | 222 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1975 | 71 | 0.010 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1994 | 23 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 1975 | 217 | 0.010 |
Why?
|
| Cadaver | 1 | 1975 | 199 | 0.010 |
Why?
|
| Sex Chromosomes | 1 | 1975 | 56 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1995 | 107 | 0.010 |
Why?
|
| Instillation, Drug | 1 | 1994 | 3 | 0.010 |
Why?
|
| Angiomatosis | 1 | 1994 | 4 | 0.010 |
Why?
|
| Respiratory Burst | 1 | 1994 | 19 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1994 | 29 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1994 | 136 | 0.010 |
Why?
|
| Bleomycin | 1 | 1994 | 99 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 1914 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1998 | 1931 | 0.010 |
Why?
|
| Vaccination | 1 | 1996 | 304 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1994 | 69 | 0.010 |
Why?
|
| Sternum | 1 | 1994 | 37 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1994 | 62 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1995 | 175 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1994 | 45 | 0.010 |
Why?
|
| Eosinophils | 1 | 1994 | 194 | 0.010 |
Why?
|
| Cats | 1 | 1994 | 285 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 1993 | 8 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 3502 | 0.010 |
Why?
|
| Endotoxins | 1 | 1993 | 36 | 0.010 |
Why?
|
| Elastin | 1 | 1993 | 8 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1993 | 83 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 174 | 0.010 |
Why?
|
| Jejunal Diseases | 1 | 1993 | 9 | 0.010 |
Why?
|
| Biological Assay | 1 | 1993 | 82 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1993 | 109 | 0.010 |
Why?
|
| Desmin | 1 | 1993 | 10 | 0.010 |
Why?
|
| Intermediate Filaments | 1 | 1993 | 16 | 0.010 |
Why?
|
| Image Enhancement | 1 | 1996 | 505 | 0.010 |
Why?
|
| Jejunum | 1 | 1993 | 76 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1993 | 51 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 1985 | 0.010 |
Why?
|
| Ossification, Heterotopic | 1 | 1993 | 32 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1995 | 502 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1993 | 103 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 401 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1998 | 1847 | 0.010 |
Why?
|
| Culture Media | 1 | 1992 | 139 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1992 | 155 | 0.010 |
Why?
|
| Aging | 1 | 1997 | 727 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1991 | 25 | 0.010 |
Why?
|
| Airway Obstruction | 1 | 1992 | 113 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 242 | 0.010 |
Why?
|
| Muscle Development | 1 | 1991 | 39 | 0.010 |
Why?
|
| Trypsin | 1 | 1990 | 94 | 0.010 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1990 | 16 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1991 | 232 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1997 | 782 | 0.010 |
Why?
|
| Neuropeptide Y | 1 | 1990 | 31 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1990 | 41 | 0.010 |
Why?
|
| Denervation | 1 | 1990 | 25 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1992 | 1014 | 0.000 |
Why?
|
| Nerve Fibers | 1 | 1990 | 40 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1996 | 1261 | 0.000 |
Why?
|
| Actins | 1 | 1993 | 467 | 0.000 |
Why?
|
| Endothelins | 1 | 1989 | 26 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1989 | 100 | 0.000 |
Why?
|
| Endothelium | 1 | 1989 | 59 | 0.000 |
Why?
|
| Diazepam Binding Inhibitor | 1 | 1989 | 1 | 0.000 |
Why?
|
| Chitin | 1 | 1989 | 10 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1991 | 464 | 0.000 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1988 | 107 | 0.000 |
Why?
|
| Swine | 1 | 1989 | 588 | 0.000 |
Why?
|
| Angioedema | 1 | 1987 | 4 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1987 | 40 | 0.000 |
Why?
|
| Vincristine | 1 | 1987 | 99 | 0.000 |
Why?
|
| Complement C4b | 1 | 1987 | 33 | 0.000 |
Why?
|
| Urticaria | 1 | 1987 | 15 | 0.000 |
Why?
|
| Surface Properties | 1 | 1987 | 126 | 0.000 |
Why?
|
| Thiobarbiturates | 1 | 1986 | 5 | 0.000 |
Why?
|
| BK Virus | 1 | 1987 | 23 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1987 | 86 | 0.000 |
Why?
|
| Prednisone | 1 | 1987 | 242 | 0.000 |
Why?
|
| Ascitic Fluid | 1 | 1986 | 37 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1987 | 278 | 0.000 |
Why?
|
| Urine | 1 | 1987 | 94 | 0.000 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 1986 | 7 | 0.000 |
Why?
|
| Cardiolipins | 1 | 1986 | 16 | 0.000 |
Why?
|
| Peptides | 1 | 1989 | 656 | 0.000 |
Why?
|
| Thrombophlebitis | 1 | 1986 | 24 | 0.000 |
Why?
|
| Blood Coagulation Factors | 1 | 1986 | 20 | 0.000 |
Why?
|
| Arteries | 1 | 1986 | 171 | 0.000 |
Why?
|
| Corticotropin-Like Intermediate Lobe Peptide | 1 | 1985 | 1 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1985 | 18 | 0.000 |
Why?
|
| Neurotensin | 1 | 1985 | 10 | 0.000 |
Why?
|
| Pro-Opiomelanocortin | 1 | 1985 | 13 | 0.000 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1985 | 40 | 0.000 |
Why?
|
| Rupture, Spontaneous | 1 | 1985 | 43 | 0.000 |
Why?
|
| Hemoptysis | 1 | 1985 | 25 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1987 | 322 | 0.000 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1985 | 124 | 0.000 |
Why?
|
| Ethanol | 1 | 1987 | 273 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1987 | 664 | 0.000 |
Why?
|
| Leukemia, Myeloid | 1 | 1985 | 240 | 0.000 |
Why?
|
| Antibodies | 1 | 1986 | 348 | 0.000 |
Why?
|
| Oxidation-Reduction | 1 | 1985 | 410 | 0.000 |
Why?
|
| Recurrence | 1 | 1986 | 1190 | 0.000 |
Why?
|
| Phlebography | 1 | 1983 | 68 | 0.000 |
Why?
|
| DNA | 1 | 1988 | 1265 | 0.000 |
Why?
|
| Neurons | 1 | 1990 | 1582 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1983 | 166 | 0.000 |
Why?
|
| Oxygen | 1 | 1986 | 769 | 0.000 |
Why?
|
| Fluorescence | 1 | 1976 | 100 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1985 | 2562 | 0.000 |
Why?
|